利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.022 秒)

    SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS
    3.
    发明申请
    SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS 审中-公开
    选择性CDK9抑制剂的缺点

    公开(公告)号：US20140287454A1

    公开(公告)日：2014-09-25

    申请号：US14240315

    申请日：2012-08-22

    申请人： Axel Choidas ,  Bert Klebl ,  Peter Habenberger ,  Jan Eickhoff ,  Roman Thomas ,  Johannes Heuckmann

    发明人： Axel Choidas ,  Bert Klebl ,  Peter Habenberger ,  Jan Eickhoff ,  Roman Thomas ,  Johannes Heuckmann

    IPC分类号： G01N33/50

    CPC分类号： G01N33/5011 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/106 ,  G01N2800/52

    摘要： The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to a selective CDK9 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with a selective CDK9 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to a selective CDK9 inhibitor, whereby the patient is suspected to suffer from NUT midline carcinoma (NMC). The present invention also relates to a method of monitoring or predicting the efficacy of a treatment of NUT midline carcinoma (NMC), wherein treatment with a selective CDK9 inhibitor is in particular envisaged. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one rearrangement in the NUT gene for screening and/or validation of a medicament for the treatment NUT midline carcinoma (NMC) is described. Furthermore, a kit useful for carrying out the methods described herein as well as an oligo- or polynucleotide capable of detecting rearrangements in the NUT gene are provided.

    摘要翻译： 本发明涉及一种选择（a）对选择性CDK9抑制剂具有易感性的细胞，（a）组织或（a）细胞培养物的方法。 本文还描述了确定哺乳动物肿瘤细胞或癌细胞对用选择性CDK9抑制剂进行治疗的反应性的方法。 特别地，本发明提供了用于鉴定对选择性CDK9抑制剂敏感的患者或患者的体外方法，由此患者怀疑患有NUT中线癌（NMC）。 本发明还涉及监测或预测NUT中线癌（NMC）治疗功效的方法，其中特别设想用选择性CDK9抑制剂进行治疗。 还描述了在NUT基因中具有至少一个重排的（转基因）非人动物或（转基因）细胞用于筛选和/或验证用于治疗NUT中线癌（NMC）的药物的用途。 此外，提供了可用于实施本文所述方法的试剂盒以及能够检测NUT基因重排的寡核苷酸或多核苷酸。

    Self-correcting printing system
    4.
    发明授权
    Self-correcting printing system 失效

    公开(公告)号：US06964530B2

    公开(公告)日：2005-11-15

    申请号：US10764017

    申请日：2004-01-23

    申请人： Nataraj Kumar Gobbak ,  Jeetendra Kumar ,  Roman Thomas Wachter

    发明人： Nataraj Kumar Gobbak ,  Jeetendra Kumar ,  Roman Thomas Wachter

    IPC分类号： B41J3/42 ,  B41J11/42 ,  B41J11/44 ,  G06K15/00

    CPC分类号： G06K15/00

    摘要： A system and method are provided for correcting a hang condition caused by an unanticipated exception during a printing process. The method may include providing a set of predetermined rules according to which the print process modules interact to control the printing process. The method further may include monitoring, from a self-correcting module, a state of each of a plurality of the print process modules. The method may also include determining that the printing device is hung during a printing process, based on at least one predetermined rule and the state of at least one print process module, and setting the state of at least one print process module to a default condition.

    Susceptibility to HSP90-Inhibitors
    6.
    发明申请
    Susceptibility to HSP90-Inhibitors 审中-公开
    对HSP90抑制剂的敏感性

    公开(公告)号：US20110319415A1

    公开(公告)日：2011-12-29

    申请号：US13059557

    申请日：2009-08-17

    申请人： Roman Thomas ,  Kathrin Maring ,  Thomas Zander ,  Peter Frommolt ,  Kwok-kin Wong

    发明人： Roman Thomas ,  Kathrin Maring ,  Thomas Zander ,  Peter Frommolt ,  Kwok-kin Wong

    IPC分类号： A61K31/395 ,  C12Q1/68 ,  G01N33/567 ,  A61K31/5377 ,  A61P35/00 ,  A61P35/02 ,  C40B30/04 ,  C12Q1/02

    CPC分类号： G01N33/574 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N2800/52

    摘要： The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to an HSP90 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with an HSP90 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to an HSP90 inhibitor and uses of an oligo- or polynucleotide capable of detecting (an) activating mutation(s) in the KRAS gene are provided. The present invention also relates to a method of monitoring the efficacy of a treatment of a cancer characterized by the presence of at least one activating mutation in the KRAS gene, and. optionally, in the EGFR gene and/or the BRAF gene. In addition, a method of predicting the efficacy of a cancer treatment is described, in particular in a cancer that is characterized by the presence of at least one activating mutation in the KRAS gene. and. optionally, in the EGFR gene and/or the BRAF gene. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one activating mutation in the KRAS gene, and, optionally, in the EGFR gene and/or the BRAF gene for screening and/or validation of a medicament for the treatment of said cancer is described and a kit useful for carrying out the methods described herein is provided.

    摘要翻译： 本发明涉及一种选择（a）对HSP90抑制剂具有敏感性的细胞，（a）组织或（a）细胞培养物的方法。 本文还描述了确定哺乳动物肿瘤细胞或癌细胞对用HSP90抑制剂进行治疗的反应性的方法。 特别地，本发明提供了用于鉴定对HSP90抑制剂敏感的或对其敏感的患者的体外方法，以及能够检测（或）激活KRAS基因突变的寡核苷酸或多核苷酸的用途 被提供。 本发明还涉及一种监测癌症治疗功效的方法，其特征在于在KRAS基因中存在至少一种激活突变。 任选地，在EGFR基因和/或BRAF基因中。 此外，描述了预测癌症治疗功效的方法，特别是在KRAS基因中存在至少一种激活突变的癌症中。 和。 任选地，在EGFR基因和/或BRAF基因中。 另外，在KRAS基因和/或任选地在EGFR基因和/或BRAF基因中具有至少一个激活突变的（转基因）非人动物或（转基因）细胞也用于筛选和/或验证 描述了用于治疗所述癌症的药物，并提供了可用于实施本文所述方法的试剂盒。